{
  "schemaVersion": 1,
  "organisationId": "O-b35938803e6c49439c0ee482c23cd75b",
  "slug": "protagonist-therapeutics-inc",
  "name": "Protagonist Therapeutics, Inc",
  "updatedAt": "2026-10-02T15:49:02.40412Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide medicines using its proprietary drug-discovery platform. Its programs target inflammatory and immune-mediated, hematologic, and metabolic diseases, including conditions with unmet medical needs; the company describes its mission as improving patients’ lives through peptide drug discovery and development. [P147144311][https://www.protagonist-inc.com/]\n\nIts portfolio includes ICOTYDE (icotrokinra), an oral IL-23 receptor blocker approved in the United States for plaque psoriasis and licensed to Johnson & Johnson, and rusfertide, an investigational hepcidin mimetic for polycythemia vera licensed to Takeda. The company also has earlier-stage programs in areas including inflammation and obesity. [P147144313][P147144315][P147144317][P147144322][P147144323][P147144325][P147144327]\n\nProtagonist is headquartered in Newark, California, and has a wholly owned subsidiary in Brisbane, Australia. It reported 132 full-time-equivalent employees at year-end 2025. For 2025, it reported $46.016 million in collaboration and license revenue and stated that it had not generated revenue from product sales. [P76238849][P103665336][P34656536][T11359897]\n[P147144311][https://www.protagonist-inc.com/][P147144313][P147144315][P147144317][P147144322][P147144323][P147144325][P147144327][P76238849][P103665336][P34656536][T11359897][https://www.protagonist-inc.com/]",
      "updatedAt": "2026-10-02T15:49:02.40412Z"
    },
    {
      "type": "PRODUCTS",
      "text": "ICOTYDE™ (icotrokinra) is an oral peptide that blocks the IL-23 receptor. It was approved in the United States in March 2026 for moderate-to-severe plaque psoriasis in adults and eligible patients aged 12 or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Licensed to Janssen/J&J, it is also being developed for psoriatic arthritis, ulcerative colitis and Crohn’s disease. [P147144174][https://www.protagonist-inc.com/product-pipeline]\n\nMIMRYLO™ (rusfertide) is an injectable hepcidin mimetic for erythrocytosis in adults with polycythemia vera; the FDA approved it on August 28, 2026. Takeda is responsible for further development and commercialization. [P147144315][P147144175][https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder][https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/]\n\nThe development pipeline includes PN-881, an oral peptide antagonist of IL-17AA, IL-17AF and IL-17FF being studied for immune-mediated diseases including psoriasis; PN-477, a triple GLP-1/GIP/glucagon receptor agonist peptide in oral once-daily and subcutaneous once-weekly formats; and PN-458, a dual GLP-1/GIP receptor agonist peptide. PN-477 has begun a Phase 1 subcutaneous study, while Phase 1 trials for its oral format and PN-458 are planned for 2027. PN-8047 is an oral small-molecule hepcidin functional mimetic being developed as a potential complement to injectable rusfertide. [P147144317][P147144320][P147144322][P147144323][P147144325]\n\nThe company also reports IL-4 and amylin programs, but provides no further product-specific detail in the cited filing material. Reported license-and-collaboration revenue is not allocated by product, so product revenue percentages are not specified. [P147144176][P147144132]\n[P147144174][https://www.protagonist-inc.com/product-pipeline][P147144315][P147144175][https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder][https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/][P147144317][P147144320][P147144322][P147144323][P147144325][P147144176][P147144132][https://www.protagonist-inc.com/product-pipeline][https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder][https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/]",
      "updatedAt": "2026-10-02T15:49:02.40412Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Protagonist Therapeutics is headquartered in Newark, California, where it has approximately 60,600 square feet of office and laboratory space. The company’s locations page also lists Brisbane, Australia; it does not disclose employee numbers or workforce distribution by location. [P90749333][P69861234][https://www.protagonist-inc.com/locations]\n\nThe company reported no approved products for commercial sale in its FY2025 filing, and does not provide a country- or region-level breakdown of product sales or revenue. [P7241078][P31118503]\n\nIts geographic collaboration arrangements have included U.S. rights for Protagonist and rights outside the United States for Takeda; a Q2 2026 filing later reported that Takeda held an exclusive worldwide license for rusfertide following Protagonist’s opt-out from U.S. profit-and-loss sharing. These are contractual territory terms, not a report of sales by geography. [P91936225][P147144227]\n[P90749333][P69861234][https://www.protagonist-inc.com/locations][P7241078][P31118503][P91936225][P147144227][https://www.protagonist-inc.com/locations]",
      "updatedAt": "2026-10-02T15:49:02.40412Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Protagonist Therapeutics reports one operating segment, encompassing its drug discovery and development activities. Management assesses performance and allocates resources on a company-wide basis; the company does not disclose separate financial contributions for individual programs or products. Accordingly, the reported operating segment represents 100% of the business, with no reported subsegment percentages. [P31118503] The Q2 2026 filing continues to report one operating segment and presents license and collaboration revenue in aggregate, without allocating it by program. [P147144293][T16835139]\n\nRevenue disclosures describe collaboration activity rather than distinct business segments. In 2025, Takeda accounted for 100% of revenue; the company does not provide a rusfertide-only revenue percentage. [P101419720] In 2024, license and collaboration revenue was approximately 62% from Takeda and 38% from JNJ, but these partner shares are not reported as segments. [P119381838]\n[P31118503][P147144293][T16835139][P101419720][P119381838]",
      "updatedAt": "2026-10-02T15:49:02.40412Z"
    },
    {
      "type": "HISTORY",
      "text": "Protagonist’s origins date to Protagonist Pty Ltd, incorporated in Australia in September 2001 and incubated at the University of Queensland’s Institute for Molecular Bioscience; its U.S. parent, Protagonist Therapeutics, Inc., was incorporated in Delaware in 2006. Mark Smythe was a co-founder, and Dinesh V. Patel became president and CEO in 2008. [P189454450] The company reported a $9 million Series B second-tranche financing in 2014, then completed its IPO in August 2016, raising $83.6 million in net proceeds. [P189456363][P189456208][P189455874]\n\nIn 2016, Protagonist began a Phase 2b trial of PTG-100 for ulcerative colitis, which it discontinued in 2018 after a futility analysis; it pursued PN-943 as another oral integrin antagonist. [P185521448][P181859486] In 2017, it entered a worldwide collaboration with Janssen on the oral IL-23 receptor antagonist PTG-200, later expanded to include second-generation candidates. [P181861160][P175508578] Its pipeline subsequently advanced PTG-300, later known as rusfertide, and PN-943 into Phase 2 studies. [P175508569][P175509530] In 2024, Protagonist partnered with Takeda to develop and commercialize rusfertide. [T1078003][P48473381] Takeda submitted a rusfertide NDA in December 2025, which FDA accepted for Priority Review in March 2026; that month, FDA approved J&J’s ICOTYDE (icotrokinra), another product arising from Protagonist’s IL-23 receptor collaboration. [P24618094][P2647112][T16835092]\n[P189454450][P189456363][P189456208][P189455874][P185521448][P181859486][P181861160][P175508578][P175508569][P175509530][T1078003][P48473381][P24618094][P2647112][T16835092]",
      "updatedAt": "2026-10-02T15:49:02.40412Z"
    }
  ],
  "sources": [
    {
      "id": "P147144311",
      "href": "https://app.finbar.com/go?id=P147144311",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "https://www.protagonist-inc.com/",
      "href": "https://www.protagonist-inc.com/",
      "label": "www.protagonist-inc.com"
    },
    {
      "id": "P147144313",
      "href": "https://app.finbar.com/go?id=P147144313",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144315",
      "href": "https://app.finbar.com/go?id=P147144315",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144317",
      "href": "https://app.finbar.com/go?id=P147144317",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144322",
      "href": "https://app.finbar.com/go?id=P147144322",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144323",
      "href": "https://app.finbar.com/go?id=P147144323",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144325",
      "href": "https://app.finbar.com/go?id=P147144325",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144327",
      "href": "https://app.finbar.com/go?id=P147144327",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P76238849",
      "href": "https://app.finbar.com/go?id=P76238849",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P103665336",
      "href": "https://app.finbar.com/go?id=P103665336",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P34656536",
      "href": "https://app.finbar.com/go?id=P34656536",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "T11359897",
      "href": "https://app.finbar.com/go?id=T11359897",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P147144174",
      "href": "https://app.finbar.com/go?id=P147144174",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "https://www.protagonist-inc.com/product-pipeline",
      "href": "https://www.protagonist-inc.com/product-pipeline",
      "label": "www.protagonist-inc.com"
    },
    {
      "id": "P147144175",
      "href": "https://app.finbar.com/go?id=P147144175",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
      "href": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
      "label": "www.fda.gov"
    },
    {
      "id": "https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/",
      "href": "https://www.takeda.com/newsroom/newsreleases/2026/fda-approval-mimrylo/",
      "label": "www.takeda.com"
    },
    {
      "id": "P147144320",
      "href": "https://app.finbar.com/go?id=P147144320",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144176",
      "href": "https://app.finbar.com/go?id=P147144176",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144132",
      "href": "https://app.finbar.com/go?id=P147144132",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P90749333",
      "href": "https://app.finbar.com/go?id=P90749333",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P69861234",
      "href": "https://app.finbar.com/go?id=P69861234",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "https://www.protagonist-inc.com/locations",
      "href": "https://www.protagonist-inc.com/locations",
      "label": "www.protagonist-inc.com"
    },
    {
      "id": "P7241078",
      "href": "https://app.finbar.com/go?id=P7241078",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P31118503",
      "href": "https://app.finbar.com/go?id=P31118503",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P91936225",
      "href": "https://app.finbar.com/go?id=P91936225",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P147144227",
      "href": "https://app.finbar.com/go?id=P147144227",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P147144293",
      "href": "https://app.finbar.com/go?id=P147144293",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "T16835139",
      "href": "https://app.finbar.com/go?id=T16835139",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2026 Q 2)",
      "documentId": "D-1611ccc8124b4a56a1afe4f72ead4ae1"
    },
    {
      "id": "P101419720",
      "href": "https://app.finbar.com/go?id=P101419720",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P119381838",
      "href": "https://app.finbar.com/go?id=P119381838",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P189454450",
      "href": "https://app.finbar.com/go?id=P189454450",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2016 Y)",
      "documentId": "D-e10e1dfcd4834a519e96c3d6bf6c7600"
    },
    {
      "id": "P189456363",
      "href": "https://app.finbar.com/go?id=P189456363",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2016 Y)",
      "documentId": "D-e10e1dfcd4834a519e96c3d6bf6c7600"
    },
    {
      "id": "P189456208",
      "href": "https://app.finbar.com/go?id=P189456208",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2016 Y)",
      "documentId": "D-e10e1dfcd4834a519e96c3d6bf6c7600"
    },
    {
      "id": "P189455874",
      "href": "https://app.finbar.com/go?id=P189455874",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2016 Y)",
      "documentId": "D-e10e1dfcd4834a519e96c3d6bf6c7600"
    },
    {
      "id": "P185521448",
      "href": "https://app.finbar.com/go?id=P185521448",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2017 Y)",
      "documentId": "D-783b1706e9c84edba2e43872d983b981"
    },
    {
      "id": "P181859486",
      "href": "https://app.finbar.com/go?id=P181859486",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2018 Y)",
      "documentId": "D-427b8565e63847edb89c4ed93087dd46"
    },
    {
      "id": "P181861160",
      "href": "https://app.finbar.com/go?id=P181861160",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2018 Y)",
      "documentId": "D-427b8565e63847edb89c4ed93087dd46"
    },
    {
      "id": "P175508578",
      "href": "https://app.finbar.com/go?id=P175508578",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2020 Y)",
      "documentId": "D-5fa981cf20aa46669997b5a3540ad110"
    },
    {
      "id": "P175508569",
      "href": "https://app.finbar.com/go?id=P175508569",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2020 Y)",
      "documentId": "D-5fa981cf20aa46669997b5a3540ad110"
    },
    {
      "id": "P175509530",
      "href": "https://app.finbar.com/go?id=P175509530",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2020 Y)",
      "documentId": "D-5fa981cf20aa46669997b5a3540ad110"
    },
    {
      "id": "T1078003",
      "href": "https://app.finbar.com/go?id=T1078003",
      "label": "Protagonist Therapeutics, Inc — Press release (2024 Y)",
      "documentId": "D-4f20e948bc9c478e96e6d00566c2029e"
    },
    {
      "id": "P48473381",
      "href": "https://app.finbar.com/go?id=P48473381",
      "label": "Protagonist Therapeutics, Inc — Press release (2024 Y)",
      "documentId": "D-4f20e948bc9c478e96e6d00566c2029e"
    },
    {
      "id": "P24618094",
      "href": "https://app.finbar.com/go?id=P24618094",
      "label": "Protagonist Therapeutics, Inc — Full financial report (2025 Y)",
      "documentId": "D-103e49c3fbc5446db54969b59164fcf1"
    },
    {
      "id": "P2647112",
      "href": "https://app.finbar.com/go?id=P2647112",
      "label": "Protagonist Therapeutics, Inc — Press release (2026 Q 1)",
      "documentId": "D-403ec9763d3145e0a2615c22f3215a8c"
    },
    {
      "id": "T16835092",
      "href": "https://app.finbar.com/go?id=T16835092",
      "label": "Protagonist Therapeutics, Inc — Press release (2026 Q 2)",
      "documentId": "D-7e15b2a6d3d04308a479457a230057e5"
    }
  ]
}